UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2024
Commission File Number: 001-41933
Haoxi Health Technology Limited
Room 801, Tower C, Floor 8, Building 103, Huizhongli, Chaoyang District
Beijing, China
+86-10-13311587976
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
Entry into a Rebate Agreement
On April 29, 2024, Haoxi Health Technology Limited (the “Company”), through its wholly owned subsidiary, Beijing Haoxi Digital Technology Co., Ltd. (“Beijing Haoxi”), entered into a Bidding Data Promotion Rebate Agreement (the “Rebate Agreement) with Jinan Yanling Biotechnology Co., Ltd. and its subsidiaries and affiliated companies (collectively, “Yanling”).
Pursuant to the Rebate Agreement, Beijing Haoxi has agreed to provide comprehensive advertising and promotion services to Yanling through advertising platforms, such as Jinri Toutiao (Today’s Headlines), Douyin, and Xigua Video. The Rebate Agreement sets up a rebate system whereby Yanling receives a rebate based on factors such as bidding data, industry relevance, delivery and business models, and adherence to the Rebate Agreement’s requirements and thresholds. The Rebate Agreement also sets a targeted advertising placement spend of no less than RMB50 million (approximately $7 million) for Yanling within the term of the Rebate Agreement, which term is from January 1, 2024 to December 31, 2024. The Rebate Agreement contains other customary obligations and rights of the parties.
The foregoing description of the Rebate Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Rebate Agreement, a copy of which is attached hereto as Exhibit 10.1.
On May 7, 2024, the Company issued a press release announcing the entry into the Rebate Agreement. A copy of the press release is attached hereto as Exhibit 99.1.
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | Haoxi Health Technology Limited |
| | | |
| Date: May 7, 2024 | By: | /s/ Zhen Fan |
| | Name: | Zhen Fan |
| | Title: | Chief Executive Officer |
2
